{"id":17888,"date":"2026-04-03T09:46:55","date_gmt":"2026-04-03T09:46:55","guid":{"rendered":"https:\/\/www.peakpoint.pk\/en\/2026\/04\/03\/itvisma-approval-sma-access\/"},"modified":"2026-04-03T10:03:31","modified_gmt":"2026-04-03T10:03:31","slug":"itvisma-approval-sma-access","status":"publish","type":"post","link":"https:\/\/www.peakpoint.pk\/en\/2026\/04\/03\/itvisma-approval-sma-access\/","title":{"rendered":"Itvisma Approval Opens New SMA Treatment Access"},"content":{"rendered":"

The U.S. Food and Drug Administration has approved Itvisma<\/strong> (onasemnogene abeparvovec-brve) for the treatment of Spinal Muscular Atrophy in adult and pediatric patients aged two years and older who carry a confirmed SMN1 gene mutation, a move that extends gene therapy options beyond infancy. The Itvisma approval represents a significant step in targeting the root cause of SMA rather than focusing solely on symptom management.<\/p>\n

Itvisma uses an AAV9 viral vector to deliver a working copy of the SMN1 gene into cells via a single intrathecal injection into the cerebrospinal fluid. This route of administration concentrates the therapy near motor neurons and allows effective dosing that is less dependent on body weight, with the aim of restoring SMN protein production and slowing or halting disease progression to improve motor milestones such as sitting, standing and walking.<\/p>\n

Although the active gene construct is the same as that in earlier infant-targeted treatments, the formulation and delivery for this indication differ from neonatal products. The concentrated preparation and intrathecal administration are specifically designed for older children and adults, seeking to reach motor neurons more efficiently in that population.<\/p>\n

The FDA granted the application Fast Track and Breakthrough Therapy designations, reflecting the urgent unmet need for therapies for patients older than two who were previously ineligible. As Vinay Prasad, M.D., M.P.H., the FDA\u2019s Chief Medical and Scientific Officer, observed, ‘Today\u2019s approval shows the power of gene therapies and offers treatment to patients across the SMA disease spectrum.’ The Itvisma approval therefore opens new clinical possibilities for a wider range of patients living with SMA.<\/p>\n

Alongside potential benefit, the label includes important safety guidance. The FDA has included a boxed warning for hepatotoxicity, and clinical data highlight risks of liver and heart injury, especially in adult patients with pre-existing chronic conditions. Healthcare providers are advised to monitor liver function closely after administration and remain vigilant for signs of cardiotoxicity as part of post-treatment surveillance.<\/p>\n

In Pakistan the announcement has been met with cautious optimism. SMA prevalence in the country is elevated in part due to high rates of consanguineous marriages, while the absence of a robust newborn screening program means many cases remain undiagnosed. Local advocates such as the Strive Eradication of Disability Foundation warn of a ‘billion-rupee’ affordability barrier: gene therapies of this class can cost millions per dose, leaving them inaccessible without major government funding or international donor programs.<\/p>\n

Health campaigners are calling on Pakistani authorities to create a national SMA registry and to engage manufacturers, including companies behind earlier SMA gene therapies, on access pricing and risk-sharing arrangements. For patients and families in Pakistan the Itvisma approval is a promise of medical progress, but realizing that promise will require policy action and innovative financing to bridge the gap between scientific advances and real-world access.<\/p>\n","protected":false},"excerpt":{"rendered":"

Itvisma approval expands FDA-approved SMA therapy for patients aged two and older; Pakistani advocates push for affordable access and a national SMA registry.<\/p>\n","protected":false},"author":7,"featured_media":17887,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[2563],"class_list":["post-17888","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health-education","tag-sma"],"_links":{"self":[{"href":"https:\/\/www.peakpoint.pk\/en\/wp-json\/wp\/v2\/posts\/17888","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.peakpoint.pk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.peakpoint.pk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.peakpoint.pk\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.peakpoint.pk\/en\/wp-json\/wp\/v2\/comments?post=17888"}],"version-history":[{"count":1,"href":"https:\/\/www.peakpoint.pk\/en\/wp-json\/wp\/v2\/posts\/17888\/revisions"}],"predecessor-version":[{"id":17889,"href":"https:\/\/www.peakpoint.pk\/en\/wp-json\/wp\/v2\/posts\/17888\/revisions\/17889"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.peakpoint.pk\/en\/wp-json\/wp\/v2\/media\/17887"}],"wp:attachment":[{"href":"https:\/\/www.peakpoint.pk\/en\/wp-json\/wp\/v2\/media?parent=17888"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.peakpoint.pk\/en\/wp-json\/wp\/v2\/categories?post=17888"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.peakpoint.pk\/en\/wp-json\/wp\/v2\/tags?post=17888"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}